Physician profile
William B King
NPI 1851399349
$480.85
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $62.05 · 2021: $47.27 · 2022: $78.64 · 2023: $22.56 · 2024: $49.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $72.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $72.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $158.76 | 2019-2020 | |
| Hologic Sales and Service, LLC | $78.64 | 2022 | |
| Exeltis, USA INC. | $51.89 | 2021-2023 | Slynd |
| Therapeuticsmd, INC. | $47.02 | 2019-2021 | |
| Pfizer INC. | $46.10 | 2019-2020 | |
| Applied Medical Resources Corporation | $37.77 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $33.61 | 2024 | Arista Ah Flexitip |
| Organon LLC | $16.18 | 2024 | |
| Lupin INC. | $10.88 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.